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Background: Patient adherence is an essential factor in obtaining an effi-
cient oral anticoagulation using antivitamin K drugs (AVK), a situation with
a narrow therapeutic window. Therefore patient education and awareness are
crucial for a good management and should be based on a correct estimation of
the current situation.
Material and methods: This study included 67 hospitalized chronically
anticoagulated patients (pts) (mean age: 62.6±13.1 years; men 45.6%) who
responded to a 25-items questionnaire to assess their knowledge on AVK
therapy management. Laboratory and clinical data were used to determine
INR value at admission, as well as to calculate CHADS2-VASC and HAS-
BLED scores for patients with atrial fibrillation (AF).
Results: The majority of pts (61.8%) were receiving AVK for AF, the
others having a mechanical prosthesis and previous thromboembolic dis-
ease or stroke. In the AF group, mean CHADS2-VASC score was 3.1±1.5,
while average HAS-BLED score was 1.8±1.2. More than half of all pts
(52.9%) had at admission an INR outside of the therapeutic range, with the
majority (42.1%) having a low INR. A correct INR value was predicted by
the education level (higher education), the diagnostic indication (pts with
mechanical prosthesis being best managed), and the concomitant use of
other antithrombotic therapies. Pts presenting with a therapeutic INR had
a trend towards longer treatment duration than those outside the thera-
peutic range (62±72 vs 36±35 months, p=0.06). There was no correlation
between admission INR and pts living conditions, INR monitoring fre-
quency, bleeding history. 
Conclusions: In a tertiary cardiology center, more than half pts receiving
AVK are admitted with an INR outside the therapeutic range. Pts with
mechanic prosthesis and complex antithrombotic regimens appear as most
careful with INR monitoring. Identifying pts groups with lowest therapeutic
range rate could help attending physicians educate pts focusing on specific
awareness issues. 
0579
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Purpose: The CHA2DS2-VASc score has been validated to stratify the risk
of thromboembolism and accurately predicts the risk of stroke in patient with
non-valvular atrial fibrillation. We sought to investigate how accurately this
score predicts the risk of stroke and death in patients with atrial flutter. 
Methods: Between July 1998 and December 2011, 197 consecutive
patients, hospitalised for atrial flutter, were enrolled in the cohort. All patients
were followed-up at least 6 months and cardiovascular events recorded. The
endpoint was defined as the first occurrence of stroke or death. The Cox anal-
ysis was adjusted on warfarin, antiplatelet and antiarrhythmic treatments at
discharge. 
Results: Mean age was 67±13 years and 152 (77%) were men. At baseline,
92 patients (47%) had hypertension, 33 (17%) diabetes, and 10 (5%) had a
history of stroke or thromboembolism. CHA2DS2-VASc score was = 0 in 26
(13%), = 1 in 36 (18%), and ≥2 in 135 (69%) patients. Seventy-seven events
occurred during a mean follow-up of 4.7±3.7 years. As shown in the Kaplan
Meier curves (figure) patients with a CHA2DS2-VASc score ≥2 were at higher
risk of stroke or death.
The adjusted Cox model showed that a CHA2DS2-VASc score ≥2 was a
predictor of risk of stroke or death with a hazard ratio of 2.17 (95%CI 1.21-
3.90, p=0.009). 
Conclusion: These results suggest that a CHA2DS2-VASc score ≥2 is asso-
ciated with a higher risk of stroke and deaths, at mid-term follow-up, in
patients with atrial flutter.
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